MX2020003591A - Constructos del virus recombinante no patogenico de la enfermedad de marek que codifica multiples antigenos heterologos. - Google Patents

Constructos del virus recombinante no patogenico de la enfermedad de marek que codifica multiples antigenos heterologos.

Info

Publication number
MX2020003591A
MX2020003591A MX2020003591A MX2020003591A MX2020003591A MX 2020003591 A MX2020003591 A MX 2020003591A MX 2020003591 A MX2020003591 A MX 2020003591A MX 2020003591 A MX2020003591 A MX 2020003591A MX 2020003591 A MX2020003591 A MX 2020003591A
Authority
MX
Mexico
Prior art keywords
disease virus
constructs encoding
heterologous antigens
encoding multiple
recombinant non
Prior art date
Application number
MX2020003591A
Other languages
English (en)
Inventor
Ian Tarpey
Stephanie M Cook
Mohamad Morsey
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2020003591A publication Critical patent/MX2020003591A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • A61K39/255Marek's disease virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17Newcastle disease virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • C12N15/869Herpesviral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16311Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16311Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16341Use of virus, viral particle or viral elements as a vector
    • C12N2710/16343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/10011Birnaviridae
    • C12N2720/10034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18111Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

La presente invención describe constructos del virus no patogénico multivalente recombinante de la enfermedad de Marek que codifica y expresa los antígenos extraños de tres o más virus aviares, junto con los métodos de uso de las vacunas de virus multivalente de las aves de corral.
MX2020003591A 2017-10-12 2018-10-11 Constructos del virus recombinante no patogenico de la enfermedad de marek que codifica multiples antigenos heterologos. MX2020003591A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762571524P 2017-10-12 2017-10-12
US201862729673P 2018-09-11 2018-09-11
PCT/EP2018/077725 WO2019072964A1 (en) 2017-10-12 2018-10-11 RECOMBINANT NON-PATHOGENIC MAREK DISEASE VIRUS CONSTRUCTS ENCODING MULTIPLE HETEROLOGOUS ANTIGENS

Publications (1)

Publication Number Publication Date
MX2020003591A true MX2020003591A (es) 2020-07-22

Family

ID=63878656

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003591A MX2020003591A (es) 2017-10-12 2018-10-11 Constructos del virus recombinante no patogenico de la enfermedad de marek que codifica multiples antigenos heterologos.

Country Status (7)

Country Link
US (2) US11229698B2 (es)
EP (1) EP3694987A1 (es)
JP (1) JP2021500876A (es)
CN (1) CN111542599A (es)
BR (1) BR112020007213A2 (es)
MX (1) MX2020003591A (es)
WO (1) WO2019072964A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE061405T2 (hu) * 2016-06-17 2023-06-28 Intervet Int Bv Nem patogén Marek-betegség vírus konstruktok, amelyek fertõzõ laryngotracheitis vírus és fertõzõ bursitis vírus antigéneket kódolnak
JP2023506919A (ja) 2019-12-20 2023-02-20 インターベット インターナショナル ベー. フェー. 多価hvtベクターワクチン
CN112206317B (zh) * 2020-10-12 2023-09-22 浙江省淡水水产研究所 一种草鱼出血病二价核酸菌蜕疫苗的制备方法
WO2022136623A1 (en) 2020-12-24 2022-06-30 Intervet International B.V. Multivalent hvt vector vaccine
WO2023213946A1 (en) 2022-05-05 2023-11-09 Intervet International B.V. New multivalent hvt vector vaccine

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965138A (en) 1985-09-06 1999-10-12 Syntro Corporation Recombinant chimeric virus and uses thereof
US5834305A (en) 1985-09-06 1998-11-10 Syntro Corporation Attenuated herpesvirus, herpesvirus which include foreign DNA encoding an amino acid sequence and vaccines containing same
US6121043A (en) 1985-09-06 2000-09-19 Syntro Corporation Recombinant herpesvirus of turkeys comprising a foreign DNA inserted into a non-essential region of the herpesvirus of turkeys genome
US5961982A (en) 1985-09-06 1999-10-05 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
US5928648A (en) 1985-09-06 1999-07-27 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
WO1987004463A1 (en) 1986-01-27 1987-07-30 Syntro Corporation Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
ES2070997T3 (es) 1989-12-04 1995-06-16 Akzo Nobel Nv Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos.
WO1992003554A1 (en) 1990-08-24 1992-03-05 Arthur Webster Pty. Ltd. Infectious laryngotracheitis virus vaccine
US6183753B1 (en) 1994-08-09 2001-02-06 Schering-Plough Veterinary Corp. Recombinant chimeric virus and uses thereof
US6913751B2 (en) 1992-06-12 2005-07-05 Schering-Plough Veterinary Corporation Recombinant avian herpesvirus useful in vaccine production
US5853733A (en) 1993-02-26 1998-12-29 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
US6875856B2 (en) 1993-09-24 2005-04-05 Syntro Corporation Recombinant infectious laryngotracheitis virus and uses thereof
FR2728795B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
FR2728794B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
US6299882B1 (en) 1999-04-09 2001-10-09 Schering Corporation UL54.5 of Marek's disease virus (MDV)
US6764684B2 (en) 2001-09-28 2004-07-20 Zeon Corporation Avian herpesvirus-based recombinant infectious bursal disease vaccine
CN101210248A (zh) * 2006-12-30 2008-07-02 河南农业大学 一种ILTV gD糖蛋白核苷酸序列和氨基酸序列及其重组的病毒疫苗以及该疫苗的应用
JP2008228658A (ja) 2007-03-20 2008-10-02 Nippon Zeon Co Ltd 新規なプロモーター、これを有する組み換え七面鳥ヘルペスウイルス、及びこれを利用した家禽用ワクチン
TWI468157B (zh) 2009-04-29 2015-01-11 Intervet Int Bv 形成錠劑的方法,進行該方法的系統及包含該錠劑的包裝物
US8932604B2 (en) 2011-10-21 2015-01-13 Intervet Inc. Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
WO2013057235A1 (en) 2011-10-21 2013-04-25 Intervet International B.V. Recombinant nonpathogenic mdv vector providing multivalent immunity
US9101598B2 (en) 2011-11-30 2015-08-11 Merial, Inc. Recombinant Gallid herpesvirus 3 (MDV serotype 2) vectors expressing antigens of avian pathogens and uses thereof
US9114108B2 (en) 2011-11-30 2015-08-25 Merial, Inc. Recombinant HVT vectors expressing antigens of avian pathogens and uses thereof
PL2785373T3 (pl) * 2011-11-30 2020-06-01 Boehringer Ingelheim Animal Health USA Inc. Rekombinowane wektory HVT wyrażające antygeny ptasich patogenów i ich zastosowania
EP2644702A1 (en) * 2012-03-30 2013-10-02 Ceva Sante Animale Multivalent recombinant avian herpes virus and vaccine for immunizing avian species
US9555016B2 (en) 2013-06-10 2017-01-31 Covidien Lp Lytic agents for use in treating intravascular clots
EP2845904A1 (en) 2013-09-06 2015-03-11 Ceva Sante Animale Recombinant Marek's disease viruses and uses thereof
AR103245A1 (es) * 2014-12-24 2017-04-26 Intervet Int Bv Vacuna vectorial basada en hvt (herpes virus de los pavos) frente a nd (enfermedad de newcastle) - ibd (enfermedad de gumboro) mejorada
HUE061405T2 (hu) * 2016-06-17 2023-06-28 Intervet Int Bv Nem patogén Marek-betegség vírus konstruktok, amelyek fertõzõ laryngotracheitis vírus és fertõzõ bursitis vírus antigéneket kódolnak
PL3554536T3 (pl) 2016-12-14 2023-03-06 Boehringer Ingelheim Animal Health USA Inc. Rekombinowane wektory hvt wyrażające wiele antygenów patogenów ptasich oraz szczepionki je zawierające

Also Published As

Publication number Publication date
US11229698B2 (en) 2022-01-25
US20200323978A1 (en) 2020-10-15
JP2021500876A (ja) 2021-01-14
US20220088187A1 (en) 2022-03-24
BR112020007213A2 (pt) 2020-10-13
RU2020115458A (ru) 2021-11-12
EP3694987A1 (en) 2020-08-19
WO2019072964A1 (en) 2019-04-18
RU2020115458A3 (es) 2022-03-17
CN111542599A (zh) 2020-08-14

Similar Documents

Publication Publication Date Title
MX2020003591A (es) Constructos del virus recombinante no patogenico de la enfermedad de marek que codifica multiples antigenos heterologos.
MY173856A (en) Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
MX361893B (es) Vectores recombinantes de herpesvirus 3 galido (mdv serotipo 2) que expresan antigenos de patogenos de aves y sus usos.
PH12019501366A1 (en) Recombinant hvt vectors expressing multiple antigens of avian pathogens, and vaccines comprising them
IN2014CH00396A (es)
MX2020003760A (es) Formulaciones de niraparib.
MX344103B (es) Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle.
MX2017005661A (es) Celulas de mamifero que expresan antigenos de citomegalovirus.
WO2015134368A3 (en) Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
PH12020551716A1 (en) Anti-ror antibody constructs
MX2020004094A (es) Metodos para administrar inmunoterapia con receptores de antigeno quimerico.
JOP20190088A1 (ar) نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
TN2014000518A1 (en) Reassortant btv and ahsv vaccines
MX2018015756A (es) Construcciones de virus de la enfermedad de marek recombinantes no patogenicas codificadoras de antigenos del virus de la laringotraqueitis infecciosa y del virus de la enfermedad bursal infecciosa.
MX2019004183A (es) Secuencia de nucleotidos que expresa una proteina de anclaje a exosoma para su uso como vacuna.
MA40624A (fr) Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant
MX2011004219A (es) Vacuna contra el virus de la peste equina africana.
MX2017009889A (es) Vacuna a base del citomegalovirus, expresando la glicoproteína del virus del ébola.
CA3045626A1 (en) Bovine herpesvirus type 1 (bohv-1) vector against bovine respiratory disease complex
MX351642B (es) Vacuna para virus de leucemia felina recombinante que contiene gen de envoltura del virus de leucemia felina optimizado.
IL282465A (en) Assemble 4/91 IBV with heterologous spike protein
PH12018500372A1 (en) Fcv recombinant vaccines and uses thereof
MX2020008779A (es) Sistemas de vectores virales recombinantes que expresan genes de paramixovirus felino exogenos y vacunas elaboradas a partir de estos.
AR113755A1 (es) Constructos de virus de la enfermedad de marek no patógenos recombinantes que codifican antígenos heterólogos múltiples